- Home
- USEG vs ALVR Comparison
USEG vs ALVR Comparison
Compare USEG & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- ALVR
- Stock Information
- Founded
- USEG 1966
- ALVR 2013
- Country
- USEG United States
- ALVR United States
- Employees
- USEG N/A
- ALVR N/A
- Industry
- USEG Oil & Gas Production
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USEG Energy
- ALVR Health Care
- Exchange
- USEG Nasdaq
- ALVR Nasdaq
- Market Cap
- USEG 80.1M
- ALVR 48.8M
- IPO Year
- USEG N/A
- ALVR 2020
- Fundamental
- Price
- USEG $2.44
- ALVR $10.06
- Analyst Decision
- USEG Strong Buy
- ALVR
- Analyst Count
- USEG 2
- ALVR 0
- Target Price
- USEG $2.75
- ALVR N/A
- AVG Volume (30 Days)
- USEG 11.0M
- ALVR 44.3K
- Earning Date
- USEG 03-25-2025
- ALVR 03-14-2025
- Dividend Yield
- USEG N/A
- ALVR N/A
- EPS Growth
- USEG N/A
- ALVR N/A
- EPS
- USEG N/A
- ALVR N/A
- Revenue
- USEG $22,257,000.00
- ALVR N/A
- Revenue This Year
- USEG N/A
- ALVR N/A
- Revenue Next Year
- USEG $12.17
- ALVR N/A
- P/E Ratio
- USEG N/A
- ALVR N/A
- Revenue Growth
- USEG N/A
- ALVR N/A
- 52 Week Low
- USEG $0.81
- ALVR $7.96
- 52 Week High
- USEG $6.40
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- USEG 57.30
- ALVR 49.51
- Support Level
- USEG $2.13
- ALVR $9.40
- Resistance Level
- USEG $2.59
- ALVR $10.40
- Average True Range (ATR)
- USEG 0.67
- ALVR 0.86
- MACD
- USEG -0.04
- ALVR 0.14
- Stochastic Oscillator
- USEG 14.25
- ALVR 84.00
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.